NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM

Tucson, AZ, July 29, 2021 --( PR.com )-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke. Click here to read more TUCSON, AZ, July 15, 2026 — NuvOx Therapeutics, Inc. (“NuvOx Therapeutics”, “NuvOx”, or the “Company”) today announces that its wholly owned subsidiary, NuvOx Pharma LLC, has been granted Fast Track Tucson, Arizona — April 30, 2026 — NuvOx Therapeutics (“NuvOx”), a clinical-stage biotechnology company developing oxygen therapeutics for life-threatening hypoxemic conditions, today announced positi Tucson, AZ – April 22, 2026 – Today NuvOx Therapeutics, Inc. (“NuvOx” or the “Company”), a clinical stage biopharmaceutical company developing a novel platform of oxygen therapeutics, today announce

The release as fetched from its publisher. nuvoxtherapeutics.com ↗